论文部分内容阅读
目的观察注射用阿奇霉素联合盐酸氨溴索注射液治疗小儿支原体肺炎的临床效果。方法选取2012年12月—2014年12月收治的小儿支原体肺炎患儿90例,随机分为对照组和观察组各45例。对照组给予注射用阿奇霉素治疗,观察组在对照组的基础上联合盐酸氨溴索注射液治疗,两组均治疗7 d。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果对照组总有效率为82.22%,观察组为95.56%,两组比较差异有统计学意义(χ2=4.050,P<0.05)。对照组肺部啰音消失、止咳、退热及住院时间分别为(6.8±2.5)、(6.8±1.7)、(3.9±1.7)、(7.7±2.3)d,观察组分别为(5.1±2.4)、(4.9±1.6)、(2.4±1.2)、(6.1±2.2)d,两组比较差异均有统计学意义(t=3.291、5.460、4.836、3.372,均P<0.05)。对照组不良反应发生率为22.22%,观察组为4.44%,两组比较差异有统计学意义(χ2=6.154,P<0.05)。结论对支原体肺炎患儿采用注射用阿奇霉素联合盐酸氨溴索注射液治疗的效果显著,可改善患儿的肺部体征,降低不良反应发生率,促进患儿病情愈合,安全有效,可作为临床对小儿支原体肺炎的首选治疗方式。
Objective To observe the clinical effect of azithromycin injection and ambroxol hydrochloride injection in the treatment of mycoplasma pneumonia in children. Methods Ninety children with mycoplasma pneumonia admitted from December 2012 to December 2014 were randomly divided into control group and observation group with 45 cases each. The control group was treated with azithromycin for injection. The observation group was treated with Ambroxol Hydrochloride Injection on the basis of the control group. Both groups were treated for 7 days. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate was 82.22% in the control group and 95.56% in the observation group. There was significant difference between the two groups (χ2 = 4.050, P <0.05). The pulmonary rales disappeared, cough, fever and hospital stay were (6.8 ± 2.5), (6.8 ± 1.7), (3.9 ± 1.7) and (7.7 ± 2.3) days respectively in the control group and (5.1 ± 2.4 ), (4.9 ± 1.6), (2.4 ± 1.2) and (6.1 ± 2.2) d, respectively. There was significant difference between the two groups (t = 3.291,5.460,4.836,3.372, all P <0.05). The incidence of adverse reactions in the control group was 22.22%, the observation group was 4.44%, the difference was statistically significant (χ2 = 6.154, P <0.05). Conclusion The treatment of mycoplasma pneumonia with azithromycin in combination with ambroxol hydrochloride injection is effective in improving the lung signs and reducing the incidence of adverse reactions in children and promoting the healing of the disease in children and is safe and effective Mycoplasma pneumonia in children preferred treatment.